Clinical trials: Coagulation Protein Disorders
Hemophilia A
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery.
- Trial name
- NCT00157105
- Testing
- Antihemophilic factor, recombinant, manufactured protein-free
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A
Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis in pediatric patients aged 0 to 11 years with severe or moderate congenital hemophilia A without factor…
- Trial name
- ZEBRHA 3 (NCT07838194)
- Testing
- NXT007
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Chronic Myeloproliferative Disorders, Leukemia
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who have locally advanced or metastatic cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004258
- Testing
- cilengitide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Indiana University
Von Willebrand Disease, Type 1
Evaluation of Bleeding Score in Egyptian Patients With vWD Type I and Correlate it With Laboratory Parameters
Applying the ISTH-BAT questionnaire on Egyptian patients with type I VWD aiming to correlate the BS with the laboratory findings
- Trial name
- NCT03915873
- Testing
- The von Willebrand Antigen level
- Volunteers
- 20 people
- Sponsor
- Assiut University
Hemophilia
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
The purpose of this study is to investigate the safety of a test drug to treat hemophilia in adult men.
- Trial name
- NCT03996486
- Testing
- BAY1093884
- Sponsor
- Bayer
Severe Hemophilia A
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A…
- Trial name
- HAVEN 7 (NCT04431726)
- Testing
- Emicizumab
- Where
- 32 sites in United States, Australia and 12 more
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Multiple Trauma, Coagulation Disorder
Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma
Coagulation factor XIII (FXIII), a plasma transglutaminase, is known as the final enzyme of the coagulation cascade, responsible for a cross-linking of fibrin to strengthen blood clot.
- Conditions
- Multiple Trauma, Coagulation Disorder, Coagulation Factor Deficiency, Coagulation Defect; Acquired
- Trial name
- NCT03634215
- Testing
- fibrinogen plasma concentration, coagulation factor XIII activity
- Where
- 3 sites in Czechia
- Volunteers
- 357 people
- Sponsor
- Masaryk Hospital Krajská zdravotní a.s.
Factor VIII Deficiency, Congenital
Hemlibra in Mild Hemophilia A
This is a single arm, phase 4, prospective, open-label, United States single-center study to determine the hemostatic characteristics of Hemlibra (emicizumab) as measured by coagulation laboratory parameters in the mild…
- Trial name
- NCT04567511
- Testing
- Emicizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana Hemophilia &Thrombosis Center, Inc.
Hemophilia A, Hemophilia B
A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
The purpose of the current Phase 1/2a single dose, dose-escalating study is to evaluate the acute safety, pharmacokinetics (PK) and pharmacodynamics (PD) properties of MOD-5014 in adult subjects with moderate/severe congenital…
- Trial name
- NCT02418793
- Testing
- MOD-5014
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- OPKO Health, Inc.
Postural Balance
Balance Evaluation in Adult Hemophilia
Introduction: Recurrent hemarthrosis in hemophilia can cause deterioration of static and dynamic balance in hemophilia. Studies in AwH report decreased dynamic balance, but consistent results regarding static balance are lacking.
- Trial name
- NCT07243912
- Testing
- Postural balance assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Ayse Merve TAT
Haemophilia A, Haemophilia B
A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
To describe the current treatment practice during 12 months for previously treated patients diagnosed with haemophilia A or haemophilia B.
- Trial name
- NCT02049099
- Where
- 12 sites in Belgium, France and 5 more
- Volunteers
- 1,658 people
- Sponsor
- Swedish Orphan Biovitrum
Hemophilia a and B
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
The goal of this clinical trial is to evaluate the safety and efficacy of KN057 in adult patients with severe Hemophilia A (coagulation factor FVIII activity <1%) or moderate-to-severe Hemophilia B (FIX activity ≤2%).
- Trial name
- NCT06747416
- Testing
- KN057
- Volunteers
- 24 people
- Sponsor
- Suzhou Alphamab Co., Ltd.
Von Willebrand Disease (VWD)
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
The main aim of the study is to check effectiveness of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (not related to trauma) bleeding episodes in pediatric and adult participants…
- Trial name
- NCT03879135
- Testing
- rVWF, rFVIII
- Where
- 33 sites in United States, Austria and 7 more
- Volunteers
- 38 people
- Sponsor
- Baxalta now part of Shire
Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
Post-acute infectious syndrome (PAIS), including post-COVID-19 condition (PCC or Long COVID), can develop after an infection and may cause persistent symptoms such as fatigue, problems with memory and concentration ("brain fog")…
- Trial name
- PAISE-AriSE (NCT07714213)
- Testing
- Aripiprazole (low-dose, 1mg)
- Where
- Germany
- Volunteers
- 138 people
- Sponsor
- Christiana Franke
Haemophilia A
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
This study will collect information on side effects and how well Esperoct® (turoctocog alfa pegol (N8-GP)) works during long-term treatment (prophylaxis) in males with haemophilia A.
- Trial name
- pathfinder9 (NCT04574076)
- Testing
- Turoctocog alfa pegol (N8-GP)
- Where
- 27 sites in Austria, Bulgaria and 13 more
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Hemophilia B
Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B
This study is designed to evaluate BeneFIX infused as prophylaxis regimens, compared with BeneFIX administered as an on-demand regimen only. In the trial, subjects will participate in 4 study periods.
- Trial name
- NCT00364182
- Testing
- Recombinant Coagulation Factor IX (BeneFIX)
- Where
- 19 sites in United States, Canada and 7 more
- Volunteers
- 50 people
- Sponsor
- Pfizer
Hemophilia A
Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A
The purpose of this study is to study the evaluation of efficacy and safety of GreenGene (Recombinant Factor VIII).
- Trial name
- NCT01568580
- Testing
- GreenGene
- Volunteers
- 71 people
- Sponsor
- Green Cross Corporation
Hemophilia
Isokinetic Strength Training On Functional Performance
Hemophilia is a congenital , recessive clotting disease featured by cerebra ( The most dangerous ) and musculoskeletal (the most common and disabling) hemorrhages .
- Trial name
- Isokinetic (NCT07035080)
- Testing
- interferential therapy, tradional physical therapy
- Volunteers
- 30 people
- Sponsor
- Kafrelsheikh University
Hemophilia
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
Research Title：Adult and adolescent hemophilia patients treated with Marstacimab: a patient Experience Registry (AMBER) Protocol Number：94250855 Protocol Version Number：version 0.3 Date：15-November-2024 Leading site：Institution…
- Trial name
- AMBER (NCT06992076)
- Testing
- Marstacimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Haemophilia A
An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.
The main objectives of this study are to compare the first and second recovery assessments and recovery when a subject changed batch and to assess whether haemostasis was achieved with Optivate® when treating a bleed.
- Trial name
- NCT02246868
- Testing
- Optivate® (Human Coagulation Factor VIII)
- Where
- 11 sites in Poland, United Kingdom
- Sponsor
- Bio Products Laboratory
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.